In this study we aimed to identify small molecules with high affinity involved in the allosteric regulation of LVIS553, a MarR member from Lactobacillus brevis ATCC367. Using high throughput screening, novobiocin was found to specifically bind LVIS553 with a K D =33.8 ± 2.9 μM consistent with a biologically relevant ligand. Structure guided site directed mutagenesis identified Lys9 as a key residue in novobiocin recognition. The results found in vitro were correlated in vivo. An increased tolerance to the antibiotic was observed when LVIS553 and the downstream putative transport protein LVIS552 were either expressed in a low copy plasmid in L. brevis or as a single copy chromosomal insertion in Bacillus subtilis. We provide evidence that LVIS553 is involved in the specific regulation of a new mechanism of tolerance to novobiocin.
The MarR family of transcriptional regulators is a diverse group of small proteins (120-207 amino acids long) that share similar structural scaffold (1) . Conversely, analysis of the amino acid sequence alignment of well characterized MarR members such as MarR (PDB ID: 1JGS), OhrR (PDB ID: 1Z91), SlyA (PDB ID: 1LJ9) and EmrR (PDB ID: 2GXG) revealed that very few amino acids are conserved (2) . Consequently, the main focus of several previous reports has been to further understand the contribution of conserved structures to DNA binding and the key roles of individual amino acids. As a result, the location of the MarR DNA binding domain was previously determined to reside within amino acids 61 to 121 (3) . Further reports have shown that mutations on residues allocated in this area have both structural and functional consequences which decrease DNA binding as shown for MarR (3), SlyA in Salmonella (4) and MdtR (YusO) in B. subtilis (5) . To date however, we are far from understanding in depth, the molecular mechanisms behind the structural modifications associated with ligand binding.
Several factors have contributed to the uncertainties that remain regarding ligand binding. First and foremost, the ability to identify specific amino acids and their associated functional involvement has been hindered by the overlapping nature of both the DNA and ligand binding motifs. In addition, attempts to examine the mechanisms in detail have been further hampered due to the overall lack of physiologically relevant ligands. Annotations for the majority of family members are usually based on in silico data without direct physiological evidence. The founding member of this family is MarR from Escherichia coli (6, 7) which has been biochemically, structurally, and phenotypically characterized. MarR binds salicylate and other phenolic compounds such as plumbagin, 2,4-dinitrophenol, and menadione in the low millimolar range (0.5-2 mM) (8, 9) .
Many orthologs have been reported thereafter and binding to salicylate has been claimed (10) though in most cases, their binding affinities are too low to be considered biologically or biochemically relevant. Other well characterized members of this family such as EmrR (11) and HucR bind small molecules in the low micromolar range (2.0 -15.0 and 11.6 μM, respectively) (12, 13) . Accordingly, we are particularly interested in identifying alternative ligands, elucidating the mechanisms by which small molecules regulate the formation and release of transcriptional regulators from the cognate DNA sequence, and discussing the molecular results under the light of its physiological consequences.
Due to their involvement in multidrug resistance and tolerance to highly toxic compounds, MarR members have been predominately studied in pathogenic microorganisms, though they are found throughout many bacterial and archaeal groups (14) . It is particularly interesting to determine how commensal bacteria such as Lactobacillus, are able to tolerate and survive to antibiotics as means of persistence in the intestinal tract or as a competitive advantage over other commensal members. Lactobacilli are in general, very resistant and capable of tolerating a wide variety of stress conditions [for a review see Lorca et al., (15) ]. L. brevis, in particular, has received a lot of attention due to its role in the spoilage of beer (16) which involves the induction of efflux pumps as a mechanism of hop resistance (17, 18) . By comparative genomics we determined that L. brevis has the highest number of transport proteins (13 %) involved in the uptake and efflux of drugs and toxic compounds (19, 20) . Collectively, these characteristics make L. brevis a good model for understanding how commensal bacteria respond to environmental stressors such as antibiotics, via mechanisms in which transcriptional regulators may be involved.
In this study we used LVIS553 as a model protein to locate and examine high affinity small molecules involved in the allosteric regulation of a MarR member. The identified molecule, novobiocin, was found to specifically bind LVIS553 in the low micromolar range. We provide in vivo evidence that LVIS553 is involved in the regulation of a new mechanism of tolerance to novobiocin.
Experimental Procedures
Bacterial strains -Lactobacillus brevis ATCC367 was obtained from the American Type Culture Collection (ATCC, Manassas, VA). Lactobacillus strains were grown at 37 °C in MRS broth (Difco Laboratories, Detroit, MI). Escherichia coli DH5 cells, used to carry and propagate all vectors, were grown in LuriaBertani medium (Difco). Bacillus subtilis M168 was used for heterologous gene expression. Growth was performed in LB media at 37 °C under aerobic conditions. When appropriate, media was supplemented with erythromycin, 7.5 μg/mL (for L. brevis), kanamycin, 5 μg/mL (for B. subtilis) or ampicillin, 100 μg/mL (for E. coli). All antibiotics and chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
DNA manipulations and gene cloningStandard methods were used for site directed mutagenesis, chromosomal DNA isolation, restriction enzyme digestion, agarose gel electrophoresis, ligation, and transformation (21) . Plasmids were isolated using spin miniprep kits (Qiagen, Valencia, CA) and PCR products were purified using Qiaquick purification kits (Qiagen). Mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA).
For protein expression and purification, the LVIS553 gene was amplified from L. brevis ATCC367 chromosomal DNA by PCR. The primers utilized are described in Table 1 . The plasmid p15TV-L (GeneBank accession EF456736) obtained from the Structural Genomics Consortium (SGC, Toronto) was employed as a vector. This construct also provides a N-terminal hexahistidine tag, separated from the protein by a tobacco etch virus (TEV) protease recognition site (ENLYFQGS).
Cloning in the pRV610 plasmid (22) was performed amplifying LVIS552-LVIS553 (including the complete P LVIS553 ) by PCR, using the primers described in Table 1 . Clones were confirmed by sequencing, using universal M13 primers.
For heterologous gene expression of L. brevis genes in B. subtilis, LVIS552-LVIS553 was amplified using PCR, cut with KpnI and XbaI restriction enzymes, and cloned in pSacKan (23) . Recombinant clones were obtained in E. coli DH5 and subsequently sequenced. Transformation of B. subtilis was performed by natural competence. Integration in the sacA gene was verified by the inability to utilize sucrose as a carbon source on minimal media (24) .
Protein purification -Protein purification was carried out as previously described (25) . Briefly, the His-tagged fusion proteins were overexpressed in E. coli BL21-Star(DE3) cells (Stratagene). The cells were grown in LB at 37 C to an OD 600 ~0.6 and expression induced with 0.4 mM IPTG. After addition of IPTG, the cells were incubated with shaking at 15 C overnight.
The cells were harvested, resuspended in binding buffer (500 mM NaCl, 5% Glycerol, 50 mM HEPES pH 7.5, 5 mM Imidazole), flash-frozen in liquid N 2 and stored at -70 C. The thawed cells were lysed and passed through a French Press after the addition of 0.5% NP-40 and 1 mM each of PMSF and benzamidine. The lysate was clarified by centrifugation (30 min at 17,000 rpm) and applied to a metal chelate affinity-column charged with Ni 2+ . After the column was washed, the protein was eluted from the column in elution buffer (binding buffer with 500 mM Imidazole). The hexa-histidine tag was then cleaved from the protein by treatment with recombinant His-tagged TEV protease. The cleaved protein was then resolved from the cleaved His-tag and the His-tagged protease by passing the mixture through a second Ni 2+ -column. The purified proteins were dialyzed against 10 mM HEPES, pH 7.5, 500 mM NaCl, and concentrated using a BioMax concentrator (Millipore, Billerica, MA).
Size-exclusion chromatography -100 L protein sample contained 10 mM HEPES, pH 7.5, 500 mM NaCl, 25 M LVIS553 and where indicated, 100 μM novobiocin. Following a 20 minute incubation on ice, samples were injected onto a Superose 12 10/300 GL gel filtration column (Amersham Biosciences, Piscataway, NJ) installed on an Äkta system (Amersham Biosciences) equilibrated with 10 mM HEPES pH 7.5, 500 mM NaCl. Filtration was performed at 4 °C at a flow rate of 0.5 mL/min and the protein concentration was monitored by measuring the absorbance at 280 nm. Blue dextran 2000 was used to determine the void volume. A mixture of protein molecular mass standards, containing -amylase (200 kDa), BSA (66 kDa), carbonic anhydrase (29 kDa) and cytochrome C (12.4 kDa), was applied to the column under similar conditions. The elution volumes and molecular masses of the protein standards were used to generate a standard curve from which the apparent molecular mass was determined.
Electrophoretic Mobility Shift Assays (EMSA) -EMSA for LVIS553 was performed using protein purified and concentrated according to the procedures described above. Fragments for the P LVIS552 , P LVIS553 and P LVIS554 promoter regions (Table 1) were generated by PCR using biotin prelabeled (5'-end) primers, then purified using QIAquick spin columns (Qiagen). Incubation mixtures for EMSA (20 L) contained 2.5 nM of a 5'-labelled DNA fragment, 50 mM TrisHCl pH 7.5, 150 mM KCl, 10 mM MgCl, 0.01% Triton X100, 50 ng/L Poly(dI-dC) nonspecific competitor DNA, purified LVIS553 protein (0 -100 nM) and ligand (0 -1 mM) when indicated.
After incubation for 20 min at 37 C, samples were separated on 6% acrylamidebisacrylamide nondenaturing gels in 0.5x Tris borate-EDTA buffer, pH 8.3 (TBE). Electrophoresis was performed at 100 V using ice-cold 0.5x TBE as a running buffer. DNA was then transferred from the polyacrylamide gel to the Biodyne B Positive Nylon Membrane (Pierce, Rockford, IL) by electroblotting at 380 mAmps for 40 min in 0.5x TBE. Transferred DNA was cross-linked for 15 min using a UV cross-linker equipped with 312 nm bulbs. Biotin labeled DNA was detected using a horseradish peroxidase/Super Signal Detection System (Pierce). Membranes were exposed to Kodak Xray film.
For EMSA competition assays, oligonucleotides corresponding to both strands of protected regions in the footprint assay (Table  1) were synthesized. Annealing was carried out by mixing equimolar amounts (at a concentration of 100 M) of each complementary oligonucleotide in 0.25 M TrisHCl, pH 8.0. The mixture was incubated at 95 °C for 5 min and then chilled on ice.
DNase I Footprinting -DNase I footprint assay was carried out as described previously by Zianni et al. (26) in the Plant and Microbe Genomics Facility at Ohio State University, Columbus. Briefly, 5'-VIC or 5'-FAM labeled probes were generated by PCR using primers listed in Table 1 . The reaction mix containing 750 ng labeled probe, 14 µg of LVIS553, 50 mM Tris-HCl pH 7.5, 150 mM KCl, 12.5 mM MgCl 2 , 0.5 mM CaCl 2 0.01% Triton X100, 25 ng/L Poly(dI-dC) nonspecific competitor DNA, and 0.006 U of DNase I (New England Biolabs, Ipswich, MA) was incubated for 20 min at 37 ºC. The reaction was terminated with 10mM EDTA pH 8.0. The mix was heat inactivated at 72 ºC for 10 min. The DNA fragments were purified with phenolchloroform-isoamyl alcohol (ratio 25:24:1) and precipitated with ethanol. A nondigested fragment was used for sequencing reactions with Thermo Sequence dye primer manual cycle sequencing kit (USB Corp., Cleveland, OH). The digested DNA and sequencing reaction products were analyzed with 3730 DNA analyzer and the protected regions were identified with GeneMarker (Soft genetics). , Bio-Rad) was used to monitor protein unfolding by the increase in the fluorescence of the fluorophor SYPRO Orange (Invitrogen). Fluorescence intensities were plotted against temperature for each sample well and transition curves were fitted using the Boltzmann equation using Origin 8 software (Northhampton, MA). The midpoint of each transition was calculated and compared to the midpoint calculated for the reference sample. If the difference between them was greater than 2.0 ºC, the corresponding compound was considered to be a "hit" and the experiment was repeated to confirm the effect in a dose dependent manner.
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Titration Calorimetry -Measurements were performed on a VPMicrocalorimeter (MicroCal, Northampton, MA) at 30 °C. The protein was thoroughly dialyzed against 10 mM HEPES, pH 7.5, and 500 mM NaCl. A solution of novobiocin (1 mM) was directly prepared in dialysis buffer. Each titration involved a series of 4 L injections of effector molecule into the protein solution. The mean enthalpies measured from injection of the ligand in the buffer were subtracted from raw titration data prior to data analysis with ORIGIN software (MicroCal). Titration curves were fitted by a nonlinear least squares method to a function for the binding of a ligand to a macromolecule (29) . From the curve thus fitted, the parameters H (reaction enthalpy), K A (binding constant, K A = 1/K D ), and n (reaction stoichiometry) were determined.
From the values of K A and H, the changes in free energy (G) and in entropy (S) were calculated with the equation: G = -RT lnK A = H -TS, where R is the universal molar gas constant and T is the absolute temperature.
Results
LVIS553 operon structure and binding site -In
L. brevis the MarR family (COG1846) is the most abundant and the most diverse group with 22 proteins or 15.4% of all transcription factors. These data correlates well with the high amount of drug efflux systems (13% of the total transport proteins) found in the genomes of Lactobacillus (19, 20) . In this report, we chose LVIS553 as our model protein for the first step in unveiling small regulatory molecules for this diverse group of proteins.
To determine the binding site for LVIS553, the genomic environment was analyzed (Fig. 1) . LVIS553 is encoded in the minus strand and downstream on the plus strand is encoded LVIS554. This protein is annotated as a putative Na + -driven multidrug efflux pump and classified using the Transport Classification Data base (30) within the multi antimicrobial extrusion (MATE) family, TCDB 2.A.66.1. Upstream of LVIS553 on the minus strand, is encoded LVIS552 which encodes for a protein with four predicted transmembrane domains. No characterized homologs of LVIS552 were identified on either TCDB or non-redundant databases. The genomic environment of LVIS552-LVIS553 however, was found to be conserved in L. plantarum, but not in other Lactobacillus. Interestingly, the only two other genomes where this putative operon is conserved is in Ruminococcus obeum and Blautia hydrogenotrophica. LVIS554 shares a 64% identity at the protein level with gene lp_1386 which is located in a different genomic environment than lp_0816 and lp_0817 (homologs to LVIS552 and LVIS553, respectively) suggesting that they do not belong to the same transcriptional unit.
Based on the vast literature available in which local transcriptional regulators are usually encoded upstream or downstream of the regulated genes, we amplified by PCR two fragments: the first includes the intergenic region between LVIS552-LVIS553 (P LVIS552 ) and the second harbors the LVIS553-LVIS554 (P LVIS553 ) (Fig. 1) . The protein/ DNA interaction was tested by EMSA. We found that LVIS553 binds to P LVIS553 but not to P LVIS552 (Fig. 1) . To narrow down the binding site we tested different combinations of primers within P LVIS553 including the promoter-like region upstream of LVIS554. The smallest region that binds LVIS553 was found within 130 bp of the predicted start codon of LVIS553.
To determine the binding site of LVIS553, a DNase I footprinting assay was performed. We detected a protected region of 30 nucleotides located from base +13 to base -17 of both the plus and minus strands according to +1 position of the predicted transcription start site ( Fig. 2A ). LVIS553 appears to protect a region that contains the predicted -10 region of P LVIS553 as well as the hypothetical transcription start site (Fig. 2B ). This protected region includes one imperfect inverted repeat (5'-TAaTGGActtaTCCAcTA-3') flanked on both sides by AT rich sequences. The protected sequence also has two short mirror sequences 5'-TTATCcaCTATT-3' and 5'-AATTTAAgAATTTAA-3' that partially overlap the inverted repeats.
To confirm whether this protected region is the binding site for LVIS553, a competition assay was performed with the small, unlabeled double stranded DNA of 30 bp, identified by DNase I footprinting. The LVIS553/P LVIS553 interaction was incubated with increasing concentrations of this unlabeled DNA (FP-553). A 50 % disruption of the LVIS553/P LVIS553 complex was found at 1:1 ratio (P LVIS553 DNA: FP-553 DNA) with a complete disruption at 1:10 ratio (Fig. 2C) .
Screening of the small molecule library for binding to LVIS553 -The expression of LVIS553 from L. brevis ATCC367 produced a soluble polypeptide (see "Experimental Procedures" for details) with an apparent molecular mass of 17.2 kDa and a yield of 12 mg/L. LVIS553 was tested for binding against 158 metabolic scaffolds (31) and the Prestwick library by high-throughput protein stability assay, using fluorometry (27, 32) . First, the thermal melt conditions for LVIS553 were established, to generate interpretable unfolding data (described in "Experimental procedures"). The midpoint transition was established at 56.6 °C. The compounds that induced a shift in the midpoint transition temperature (T m ) of LVIS553 by more than 2.0 °C were considered "hits". We found that LVIS553 showed an increase in T m with carbamazepide (∆T m =4.1 °C), novobiocin (∆T m =3.0 °C), canrenoic acid (∆T m =2.9 °C), diazoxide (∆T m =2.7 °C), pindolol (∆T m =2.5 °C) and zomepirac (∆T m =2.1 °C) ( Table 2) . These results were confirmed by analyzing the dose dependency. This was accomplished by using increasing concentrations (0 -1 mM) of each chemical. Interestingly, a common chemical scaffold was not identified among all "hit" molecules.
Effect of putative "hits" on DNA binding in vitro -P LVIS553 fragment was used to assess the effect of ligands on the protein/ DNA interaction. Carbamazepine, canrenoic acid, diazoxide, zomepirac, and pindolol tested at 100 μM or 1 mM (Fig. 3A ) had no effect on the binding ability of LVIS553 with P LVIS553 . According to EMSA results, novobiocin was the only ligand identified from screening that caused dissociation of LVIS553 from P LVIS553 (Fig. 3A) in a concentration dependent manner (Fig. 3B) .
Using the structure of novobiocin as a model (33), we attempted to determine the smallest chemical scaffold that elicited an effect on LVIS553 using EMSA assays. We found that none of the coumarin-related molecules tested (coumarin, esculin, esculetin, umbelliferone, scopoletin) had an effect on the stability of the LVIS553 -P LVIS553 complex when tested at 1 mM concentration (data not shown). Coumermycin A1 is a structurally related antibiotic that is also active on DNA gyrase (33) . We determined the effect of coumermycin A1 on the binding of LVIS553 to P LVIS553 (Fig. 3C) . EMSA experiments showed that coumermycin A1 is able to disrupt the DNA/ protein complex at lower concentrations (50 μM) than novobiocin (100 μM).
Modulation of LVIS553 activity in vivo -
The effect of novobiocin and coumermycin A1 on LVIS553 activity was assessed by measuring the expression of LVIS553 and the downstream gene LVIS552. Cells were grown in MRS broth in presence or absence of increasing concentrations of novobiocin (1 or 5 μM) or coumermycin A1 (0.1 or 0.5 μM). The difference in concentrations used for novobiocin and coumermycin A1 was due to higher sensitivity of L. brevis to the latter chemical. Novobiocin increased the expression of LVIS553 ~2000 fold at 5 μM while LVIS552 was induced at a lower level (2 fold). Coumermycin A1 was found to be a weak inducer of LVIS553 (24 fold) and had no effect on the expression of LVIS552 (Supplementary material, Fig. S1 ). The difference in expression between LVIS552 and LVIS553 is intriguing since transcriptional terminators could not be identified in the intergenic region. These results indicate that although coumermycin A1 has an apparent higher affinity for LVIS553 in vitro, as shown on the EMSA assays, the in vivo assays indicate that novobiocin might be the biologically relevant ligand for this transcriptional regulator.
To test this hypothesis the genes LVIS552 and LVIS553 (including the complete P LVIS553 ) were cloned in the low copy vector pRV610 generating pLVIS552_553 plasmid. The rationale being that if L. brevis ATCC 367 harbors a plasmid resulting in higher numbers of the transporter protein that mediate antibiotic efflux, an increased tolerance to novobiocin will be observed. L. brevis-pRV610 (L. brevis with empty plasmid as control) cells were grown with increasing concentrations of novobiocin (0.1 -5 μM). An initial growth inhibition, indicated by a 60% decrease in the optical density with respect to a culture without novobiocin, was observed at 0.5 μM (Fig. 4A ). This residual tolerance was not inhibited by concentrations up to 5 μM. Interestingly, L. brevis-pLVIS552_553 showed an increased tolerance (80% of the initial density) with 5 μM novobiocin (Fig. 4A) . These results suggest that the putative transport protein LVIS552 is involved in the efflux of novobiocin. The residual tolerance observed at 0.5 μM in L. brevis-pRV610 could be explained by the activation of multiple unspecific drug efflux systems known to be abundant in the L. brevis genome (20) .
Characterization of novobiocin-LVIS553 binding -To further characterize the LVIS553
interactions with the newly identified effector molecule, the thermodynamic properties of LVIS553 interactions with novobiocin were determined using isothermal titration calorimetry. The titration of LVIS553 followed an exothermal heat change profile giving rise to a hyperbolic binding curve (Fig. 5) . Data was fitted with Origin software using the "one set of sites model". Fig. S2A ). In MTH313, two distinctive binding sites were determined for salicylate. In the salicylate binding pocket 1 (SAL1) (2) LysB8 and ArgB16 make distinct contacts (ionic interactions or hydrogen bonds) with the salicylate molecule. These two amino acids are found at the junction of the dimerization domain and the DNA binding pocket (2) . LysB8 and ArgB16 of MTH313 are conserved in LVIS553 (Lys9 and Arg16) (Fig. 6 and Supplementary material Fig.  S2B) . Interestingly, the predicted model of LVIS553 revealed that the orientation of Lys9 side chain is twisted towards the center of the binding pocket (Fig. 6 ). Amino acids with hydrophobic characteristics were also found in the MTH313 SAL1 pocket, which are also conserved in LVIS553. Based on the location of these residues, it was proposed that the binding of a salicylate molecule to MTH313 induces a structural change in the DNA binding motif of each monomer, resulting in the twisting out of the DNA binding lobes, decreasing the binding to DNA (2) . In accordance with this model LVIS553 behaves as a dimer in solution with an apparent molecular mass of 34 kDa as determined by FPLC separation (data not shown). The addition of different concentrations of novobiocin (10, 100 or 1000 μM) to either the reaction mix or the running buffer, did not affect the oligomeric state of the LVIS553, suggesting that a similar mechanism to MTH313 might be involved in the molecular regulation by novobiocin.
An unbiased BLAST search (36) identified a large number of homologs to LVIS553, with partial sequence alignment in which Arg16 was conserved but Lys9 was not (Supplementary material, Fig. S2B ). Based on these results it was hypothesized that Arg16 might be involved in DNA binding while Lys9 might be involved in signal recognition. This was tested by changing Lys9 and Arg16 to either a small amino acid (alanine) or to an acidic amino acid (aspartic acid). All these proteins were expressed in soluble form and tested on EMSA experiments. Mutations in Arg16 (either to alanine or aspartic acid) rendered this protein unable to bind DNA, confirming that this amino acid is essential to DNA binding (Fig. 7A) . Similarly, the mutant containing a drastic shift in the amino acid charge, LVIS553 Lys9Asp, also resulted in decreased affinity for DNA (Fig. 7A ) and no effect of novobiocin was observed (data not shown).
LVIS553 Lys9Ala showed binding to P LVIS553 DNA fragment at 10 nM (as the wild type). Concentrations of novobiocin up to 1 mM had a very slight effect on the LVIS553 Lys9Ala/ P LVIS553 complex (Fig. 7B) suggesting that Lys9 is the residue involved in binding to novobiocin. The residual ligand binding activity observed might be mediated by weak interactions with other residues in the binding cavity.
The effect of LVIS553 Lys9Ala mutant was tested in vivo using Bacillus subtilis as a surrogate, due to technical difficulties associated with the genetic manipulation of L. brevis ATCC367. The genes LVIS552-LVIS553 (or its mutant variant Lys9Ala) were cloned in pSacKan and integrated in the sacA gene of B. subtilis M168. The tolerance to novobiocin was increased by ten-fold in B. subtilis LVIS552-LVIS553 when compared to B. subtilis sacA::Kan r (empty vector integrated at the sacA locus as control), with a minimal inhibitory concentration (MIC) of 5 μM and 0.5 μM, respectively. The high tolerance to novobiocin conferred by LVIS552 was reverted when by guest on September 16, 2017 http://www.jbc.org/ Downloaded from LVIS553 was mutated in Lys9 (Fig. 4B) . These results confirmed the role of Lys9 as the amino acid involved the specific binding of novobiocin.
Discussion
In this report we took an unbiased approach, using high throughput screening of small molecules library, to identify novobiocin as the specific effector molecule for LVIS553. In silico modeling of LVIS553 identified MTH313 (PDB code # 3BPX) (2) as the closest structural homolog. MTH313 is one of the few available structures with its ligand salicylate which had shed light into the mechanism of interaction small molecule/protein. Interestingly, the physiologically relevant SAL1 is found in the interface of the dimerization domain and DNA binding domain, making it difficult to discriminate residues involved in DNA binding, ligand binding, or both. A detailed analysis performed in SlyA identified several amino acids within the winged-helix region, as well as two hydrophobic residues (Leu12 and Leu126) within 1 and 6 that are required for DNA binding (4). Using structure guided mutagenesis, we aimed to identify residues involved in ligand binding within the SAL1 cavity. Arg16 is highly conserved among different MarR members. We found that an alanine substitution (LVIS553 Arg16Ala) resulted in impaired DNA binding, suggesting a role in sequence recognition.
On the contrary, Lys9 is only conserved in close homologs to LVIS553, indicating that Lys9 may be the regulatory residue involved in the specific binding of novobiocin. LVIS553 Lys9Ala showed similar affinity for DNA as the wild type strain while no further response to novobiocin was detected. Although it is speculated that the SAL1 cavity has the potential to bind a wide variety of small molecules, LVIS553 only bound novobiocin or the closely related molecule coumermycin A1. The determined affinity constants for novobiocin were in the low micromolar range, consistent with a molecule having physiological relevance. These in vitro results were correlated with the in vivo induction in gene expression of LVIS553 and its downstream gene LVIS552, a putative membrane protein.
The antibacterial property of novobiocin is well established in the literature. It targets the DNA gyrase activity which translates into pleiotropic effects on the cell, affecting DNA replication, DNA repair, recombination and ultimately cell growth (37) . The novobiocin biosynthetic cluster of Streptomyces caeruleus is positively regulated by NovG and NovE (38) . NovG is an unusual transcription factor with a predicted central helix-turn-helix DNA binding domain that specifically recognizes the sequence GTTCRACTG(N) 11 CRGTYGAAC (39) . The effect of novobiocin on NovG binding properties, if any, has not yet been reported.
We identified the DNA binding sequence for LVIS553 using footprinting assay. The protected region is 30 nt long and located on the minus strand, upstream of LVIS553, overlapping the predicted -10 region of the LVIS553 promoter. It includes a 7 bp imperfect palindrome (5'-TAaTGGActtaTCCAcTA-3') flanked on both sides by AT rich sequences. A competitive EMSA assay with the 30 nt fragment confirmed the specificity of this region. A similar arrangement of the binding sequence has been described for two other MarR members, MepR (40) and OhrR (41) .
The identification of new mechanisms of tolerance to antibiotics is very relevant. Novobiocin in particular, has been suggested as a treatment for Gram-positive infections in penicillin-resistant strains (42) . Different mechanisms of tolerance to novobiocin have been described including mutations on the DNA gyrase (33) and the activation of multidrug efflux pumps (5) . In L. brevis, the expression in trans of LVIS552-LVIS553 results in an increased tolerance to novobiocin, indicating that the putative membrane protein LVIS552 is involved in the detoxification of novobiocin. These results were confirmed using B. subtilis as a surrogate strain. We revealed that the heterologous expression of LVIS552 increased the tolerance to novobiocin four-fold. In B. subtilis, a multidrug efflux transporter MdtP (YusP) was associated with increased tolerance to several antibiotics, including fusidic acid, novobiocin, streptomycin and actinomycin D (5) . Similarly to LVIS552, the expression of MdtP is regulated by MdtR (YusO,) a MarR member encoded upstream of the multidrug efflux transporter (YusP). Kim et al. (5) reported that mutations in the regulatory protein MdtR (Arg83Lys or Ala67Thr) impaired DNA binding and resulted in a two-fold increase in tolerance to streptomycin, actinomycin D and novobiocin, as well as a five-fold increase in tolerance to fusidic acid. Interestingly, EMSA experiments with MdtR revealed binding affinities in the millimolar range for novobiocin and fusidic acid, questioning their biological significance.
In conclusion, we provide evidence that LVIS553 is involved in the specific regulation of a new mechanism of tolerance to novobiocin. In contrast to other MarR members which responses to "preconceived" ligands (i.e. salycilate) have been studied, we provide in vitro data that correlates with in vivo responses. The identification of key residues involved in the specific binding of small molecules, contributes not only the growing body of knowledge currently needed to decipher the intricate mechanism of interactions between MarR's and signal molecules, but it may also serve as a starting point for the design of innovative therapeutics in the near future. (Table 1) were used to determine the smallest DNA binding region for LVIS553. EMSA results are summarized in the inset Table. (+) Positive binding of LVIS553 using 10 nM of pure protein; (-) Negative binding using up to 500 nM of purified LVIS553 protein. 
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